Reardon Andrew bought LGND
October 2, 2026 · Form 4 insider transaction
Reardon Andrew bought 340 shares of Ligand Pharmaceuticals Incorporated at $52.27 per share, a transaction worth $17.8K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
340
Price
$52.27
Total value
$17.8K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateOctober 2, 2026
Filing dateOctober 6, 2026
Shares owned after36,854
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.